Exploring the tumor microenvironment in diffuse intrinsic pontine glioma: immunological insights and therapeutic challenges
Open Access
- 12 June 2025
- journal article
- review article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (6) , e012009
Abstract
Diffuse intrinsic pontine glioma (DIPG) is a rare and highly aggressive pediatric brain tumor with a median survival of less than 12 months. The tumor arises in the pons, making surgical resection unfeasible and limiting treatment options to palliative radiation, which offers minimal survival benefit. One of the major challenges in treating DIPG is the poorly understood tumor immune microenvironment, which has hindered the development of effective immunotherapies. DIPG tumors are considered to be immunologically cold with limited immune cell infiltration. Recent studies have begun to reveal the complex and heterogeneous immune landscape of DIPG, highlighting distinct immunological subgroups. This review aims to provide a comprehensive overview of the immune landscape of DIPG based on the latest insights, identify research gaps, and suggest potential areas for future investigation to improve treatment outcomes for patients with DIPG.Keywords
Funding Information
- HEBE Foundation (2023_LUF_00217)
This publication has 100 references indexed in Scilit:
- Computational immune infiltration analysis of pediatric high‐grade gliomas (pHGGs) reveals differences in immunosuppression and prognosis by tumor locationComputational and Systems Oncology, 2021
- Decreased natural killer cells in diffuse intrinsic pontine glioma patientsChild's Nervous System, 2020
- Regulatory B Cells2020
- Hypofractionated radiotherapy with temozolomide in diffuse intrinsic pontine gliomas: a randomized controlled trialJournal of Neuro-Oncology, 2019
- Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand?Journal of Neuro-Oncology, 2019
- Targeting Tertiary Lymphoid Structures for Tumor Immunotherapy2018
- Human pontine glioma cells can induce murine tumorsActa Neuropathologica, 2014
- B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine gliomaJournal of Neuro-Oncology, 2012
- K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomasActa Neuropathologica, 2012
- Management of pediatric pontine gliomasChild's Nervous System, 1991